- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00826046
Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)
Expanded Access of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a treatment protocol to provide patients who have failed steroid treatment for acute GVHD expanded access of Prochymal. It is anticipated that a maximum of 10 patients per month for a total of 120 patients per year will be treated according to this protocol.
Patients will be treated with Prochymal twice per week at a dose of 2 x 106 human mesenchymal stem cell (hMSC)/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
Study Type
Contacts and Locations
Study Locations
-
-
Indiana
-
Beech Grove, Indiana, United States, 46107
- Indiana BMT
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02284
- Dana Farber Cancer Institute
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must be 18 years to 70 years of age, inclusive.
- Biopsy confirmation of GVHD is strongly recommended, to exclude patients presenting with diarrhea or abnormal liver function tests caused by infection.
- Patients must have failed to respond to steroid treatment (methylprednisolone [≥1mg/kg/day] or equivalent) for Grades C-D acute GVHD.
- Prochymal must be administered not longer than 14 days after the initiation of systemic steroid therapy for acute GVHD.
- Prochymal must be administered either before or at the same time any additional GVHD therapy is administered
- Patients must have an adequate renal function as defined by Cockcroft-Gault equation:Calculated creatinine clearance (CrCl) > 30 mL/min
- Patients who are women of childbearing potential, must be non-pregnant, not breast-feeding, and use adequate contraception. Male patients must use adequate contraception.
Exclusion Criteria:
- Patient has stage 3 or 4 liver GVHD, bilirubin >6 mg/dl.
- Patient has stage 4 GI-GVHD.
- Patient has any underlying or current medical condition that would interfere with the evaluation of the patient including uncontrolled infection, sepsis, organ failure, etc or any medical condition that has a high probability of causing death in less than 30 days.
- Patient may not receive any other investigational agent (not approved by the FDA for any indication) concurrently for the duration of the protocol.
- Patient has evidence of a pulmonary infiltrate or diffuse alveolar hemorrhage and must not be likely to require more than 2 liters of oxygen via face mask or an estimated fractional inspired oxygen concentration (FiO2) of 28% via other delivery methods in order to sustain an O2 saturation of 92% during the next 3 days.
- Patient has a known allergy to bovine or porcine products
- Patient has a medical history of a solid tumor disease.
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Mahboob Rahman, MD, Mesoblast, Inc.
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 276
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Graft-Versus-Host Disease
-
University of LiegeTerminatedChronic Graft-Versus-Host Disease | Acute Graft-Versus-Host Disease | Steroid Refractory Graft-Versus-Host DiseaseBelgium
-
Jazz PharmaceuticalsCompletedAcute-graft-versus-host Disease | Graft-versus-host DiseaseUnited States, Belgium, United Kingdom, Greece, Germany, Spain, France, Italy, Austria, Canada, Bulgaria, Croatia, Poland, Portugal
-
Mesoblast, Inc.Quintiles, Inc.CompletedGrade B Acute Graft Versus Host Disease | Grade C Acute Graft Versus Host Disease | Grade D Acute Graft Versus Host DiseaseUnited States
-
Grupo Espanol de trasplantes hematopoyeticos y...CompletedChronic Graft-Versus-Host DiseaseSpain
-
National Cancer Institute (NCI)TerminatedGraft vs Host Disease | Graft-Versus-Host Disease | Chronic Graft vs. Host DiseaseUnited States
-
John LevineCompletedGVHD | Low Risk Acute Graft-versus-host Disease | Graft-versus-host-diseaseUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedGraft-Versus-Host DiseaseUnited States
-
M.D. Anderson Cancer CenterCompleted
-
AltruBio Inc.CompletedSteroid-refractory Acute Graft-versus-Host Disease | Treatment-refractory Acute Graft-versus-Host DiseaseUnited States
-
Jonsson Comprehensive Cancer CenterWithdrawnAcute Graft Versus Host Disease | Gastrointestinal Tract Acute Graft Versus Host Disease | Severe Gastrointestinal Tract Acute Graft Versus Host Disease | Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host DiseaseUnited States
Clinical Trials on Prochymal®
-
Mesoblast, Inc.Juvenile Diabetes Research FoundationCompletedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent | Juvenile DiabetesUnited States
-
Mesoblast, Inc.CompletedGraft Versus Host DiseaseUnited States
-
Mesoblast, Inc.CompletedProchymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)Myocardial InfarctionUnited States, Canada
-
Mesoblast, Inc.CompletedCrohn's DiseaseUnited States, Canada, New Zealand, Australia
-
Mesoblast, Inc.CompletedCrohn's DiseaseUnited States
-
Mesoblast, Inc.No longer availableGraft vs Host Disease | Graft-Versus-Host DiseaseUnited States, Canada
-
Mesoblast, Inc.No longer available
-
Mesoblast, Inc.CompletedGraft Versus Host DiseaseUnited States, Italy, Australia, Canada, Switzerland, United Kingdom
-
Mesoblast, Inc.CompletedPulmonary Disease, Chronic Obstructive | Pulmonary Emphysema | Chronic BronchitisUnited States
-
Mesoblast, Inc.CompletedCrohn's DiseaseUnited States, New Zealand, Australia